Cytokinetics, a South San Francisco-based biopharmaceutical company, develops muscle activators and inhibitors for diseases affecting muscle performance, with key drug candidates including aficamten and omecamtiv mecarbil. Founded in 2004, it employs 423 people and specializes in cardiac muscle function.
Cytokinetics (CYTK) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cytokinetics's actual EPS was -$1.12, beating the estimate of -$1.41 per share, resulting in a 20.28% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
